Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 33,315,225 | 38,374,895 | 36,891,026 | 35,119,963 | 16,438,956 | 160,140,065 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf.... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 33,315,225 | 38,374,895 | 36,891,026 | 35,119,963 | 16,438,956 | 160,140,065 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | ||||||
| 6 | Public support. Subtract line 5 from line 4. | 160,140,065 | |||||
Calendar year
(or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 33,315,225 | 38,374,895 | 36,891,026 | 35,119,963 | 16,438,956 | 160,140,065 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 3,819 | 3,881 | 3,659 | 3,514 | 4,009 | 18,882 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | ||||||
| 11 | Total support. Add lines 7 through 10 | 160,158,947 | |||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year (or fiscal year beginning in) ![]() |
(a) 2014 | (b) 2015 | (c) 2016 | (d) 2017 | (e) 2018 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by .035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | ||
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
||
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | ||
| 4 Amounts paid to acquire exempt-use assets | ||
| 5 Qualified set-aside amounts (prior IRS approval required) | ||
| 6 Other distributions (describe in Part VI). See instructions | ||
| 7Total annual distributions. Add lines 1 through 6. | ||
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
||
| 9 Distributable amount for 2018 from Section C, line 6 | ||
| 10 Line 8 amount divided by Line 9 amount | ||
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2018 |
(iii) Distributable Amount for 2018 |
|
|---|---|---|---|---|
|
1
Distributable amount for 2018 from Section C, line 6 |
||||
|
2
Underdistributions, if any, for years prior to 2018 (reasonable cause required-- explain in Part VI). See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2018: | ||||
| a From 2013....... | ||||
| b From 2014....... | ||||
| c From 2015....... | ||||
| d From 2016....... | ||||
| e From 2017....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2018 distributable amount | ||||
|
i
Carryover from 2013 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from 3f. | ||||
| 4Distributions for 2018 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2018 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from 4. | ||||
|
5
Remaining underdistributions for years prior to 2018, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2018. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2019. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2014...... | ||||
| b Excess from 2015..... | ||||
| c Excess from 2016..... | ||||
| d Excess from 2017..... | ||||
| e Excess from 2018..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | 18007340 |
| Software Version: | 19.1.1.0 |
Attach to Form 990 or 990-EZ.
Go to www.irs.gov/Form990 for the latest information.
| Return Reference | Explanation |
|---|---|
| Form 990, Part I, Line 1 | The American Diabetes Association Research Foundation, Inc. the Foundation secures major gifts and grants to fund diabetes-related research. |
| Form 990, Part VI, Section A, Line 1a | The main responsibilities and focus of the Foundations Board is to advance, support and promote charitable contributions by soliciting major gifts for the purpose of funding the American Diabetes Associations nationwide Research Program. The Board of Directors of the Foundation provides governance over the activities of the Foundation in accodance with the purposes, policies and procedures of the American Diabetes Association. The Board delegates to the Foundations Executive Committee responsibililty for management of the Foundation when the Board is not in session. The American Diabetes Association provides complete operational support to the Foundation including staff, facilities and administrative processes. The Foundations annual budget and audit process are governed by the American Diabetes Association Board of Directors and Audit Committee. |
| Form 990, Part VI, Section A, Line 3,7a,7b | The Foundations affairs are managed by the Foundation Board of Directors. The Board of Directors of the Foundation supervises, directs and controls the activities of the Foundation in accordance with the mission, purposes, policies and procedures of the American Diabetes Association. The Board delegates to the Foundations Executive Committee responsibility for management of the Foundation when the Board is in session. The American Diabetes Association provides complete operational support to the Foundation including staff, facilities and administrative processes. The Foundations annual budget and audit process are governed by the American Diabetes Association Board of Directors and Audit Committee. If a vacancy occurs among the Foundations officers for any reason, the Board of Directors of the American Diabetes Association shall fill such position for the unexpired portion of the term. |
| Form 990, Part VI, Section B, Line 11b | IRS Form 990 Review Process by the Governing Body The American Diabetes Association Research Foundation the Foundation draft IRS 990 is reviewed by the American Diabetes Associations management and KPMG. The final and signed IRS Form 990 was provided to the Associations Board of Directors and the Foundations Board of Directors prior to filing with the IRS. |
| Form 990, Part VI, Section B, Line 12c | Managing a Conflict of Interest To identify potential conflicts of interest with appropriate due dilligence, the Foundations Officers, Directors and Members of the Grant Review Panel must annually disclose any potential conflicts of interest. The American Diabetes Associations Audit Committee and senior staff in Legal Affairs manage the disclosure and monitoring processes of the Board. The senior staff of the Associations Scientific Medical Division manage the disclosure and monitoring processes of the Grant Review Panel. Through review of the annual disclosure and review of the agendas of relevant Board, Committee and other meetings, appropriate efforts are made in advance of the meetings to identify potential conflicts of interest. Each person also has the responsibility to report his/her own conflicts of interest actual or perceived as those conflicts may arise during a meeting. |
| Form 990, Part VI, Section B, Line 12c | Research Grants Review Committee Conflict of Interest COI within the Research Grants Review Committee is managed through a written COI policy and through COI declarations signed both before and after the review cycle. The COI for grant reviewers is self-reported. The primary considerations addressed in the COI policy and program guidelines are as follows - Institutional Individuals are required to recuse themselves from reviewing grants for scientists at the same institution, including any institutions with which they may be negotiating employment. - Financial Individuals are required to recuse themselves from reviewing grants from which they stand to gain financially if the grant is awarded co-PI, collaborator, subcontracts, etc.. - Personal Individuals are required to recuse themselves from reviewing grants for investigators with whom they either have a personal or professional relationship collaborators, colleagues or personal friends, or a long standing professional or scientific disagreement that prevents them from unbiased review. |
| Form 990, Part VI, Section B, Line 13 | The American Diabetes Association has a written whistleblower policy that applies to the American Diabetes Association Research Foundation. |
| Form 990, Part VI, Section C, Line 17 | Alabama AL97-256 Alaska N/A Arizona10145 Arkansas N/A California CT81471 Colorado 2002-3003670 Connecticut CHR.0005084 Delaware N/A District of Columbia 981855 Florida CH1618 GeorgiaCH-001422 Hawaii N/A Idaho N/A Illinois CO01-025537 Indiana103829 Iowa N/A Kansas 177-257-350 Kentucky ID 45 Louisiana 34629813X Maine CO-1247 Maryland 102 Massachusetts Attorney General 029317 Michigan MICS 10326 Minnesota N/A Mississippi 100000294 Missouri CO- 021-87 Montana N/A Nebraska N/A Nevada N/A New Hampshire 5006New Jersey CH-0581900 New Mexico 1936418 New York 01-30-65 North Carolina SL000618 North Dakota 7894 Ohio 01-0239 Oklahoma 29417396 Oregon16402 Pennsylvania 21 Rhode Island 9500233 South Carolina 641South Dakota N/A Tennessee CO1919 Texas N/A Utah 6536093-CHAR Vermont N/A Virginia N/A Washington 1100167 West Virginia N/A Wisconsin3020-800 WyomingN/A |
| Form 990, Part VI, Section B, Line 14 | The American Diabetes Association has a written Document Retention and Destruction policy that applies to the American Diabetes Research Foundation. |
| Form 990, Part VI, Section C, Line 19 | Document Disclosure The following documents are available on the American Diabetes Association website http//www.diabetes.org Board of Directors, audited Foundation financial statements, IRS Forms 990 and the whistleblower policy. Available subject to request to the American Diabetes Association Legal Affairs Department are the following current bylaws, articles of incorporation and the conflict of interest policy. |
| Form 990, Part VII, Section A, Line 4,17,18 | The Chief Executive Officer is a non-voting member of the Research Foundation Board of Directors. The Chief Executive Officer, the Chief Financial Officer and the Chief Scientific, Medical Mission Officer are compensated by the American Diabetes Association based on a standard average of 37.5 hours per week. |
| Form 990, Part VII, Section A, Line 18 and 21 | Tracey D. Brown began her tenure as Chief Executive Officer on June 1, 2018. Martha P. Clark ended her tenure as Interim Chief Executive Officer on May 31, 2018. |
| Form 990, Part XI, Line 9 | Other changes in net assets or fund balances of 640,051 reflect prior year research grant award refunds and forfeitures. |
| Form 990, Part VI, Section A, Line 2 | Pearson C. Cummin, III, Secretary-Treasurer, and Linda Cummin, Board of Directors Ambassador, have a family relationship. |
| Form 990, Part VII, Section A, Line 1a4 | The Ambassador Board position is non-voting. The Ambassador Board position recognizes long-standing and on-going significant financial and non-financial support to the American Diabetes Association Research Foundation. |
| Form 990, Part III, Line 4 | Connected for Life |
| Form 990, Part III, Line 4 | Today, more than 100 million Americans in the United States have diabetes or prediabetes an invasive, unrelenting and debilitating disease that spans all ages, geography and educational levels. This chronic disease targets children, the elderly and minority populations more than others and costs the United States 327 billion dollars each year in lost productivity. It is a global epidemic that contributes to heart disease, stroke, nerve and kidney disease and vision loss. |
| Form 990, Part III, Line 4 | The American Diabetes Association is the only organization dedicated specifically to the research, education and advocacy required to improve the lives of the 30.3 million adults and children in the U. S. with diabetes and the 84.1 million people with prediabetes. For 78 years, we have been working on the frontlines to educate at-risk populations, protect the rights of people with diabetes at work, school and other aspects of daily life, pioneer clinical and research breakthroughs and foster a pipeline of the best and brightest scientists. From research labs to the halls of the Capitol to the offices of health care practitioners to communities nationwide, we are there. We are bending the curve to help people living with diabetes and their families thrive. Why Because we envision a life free of diabetes and all its burdens, which is fueled by our mission to prevent and cure diabetes and to improve the lives of all people affected by diabetes. |
| Form 990, Part III, Line 4 | DIABETES RESEARCH |
| Form 990, Part III, Line 4 | Diabetes is an extremely complex disease, caused by a combination of various genetic and environmental factors that progressively lead to an inability to produce or effectively utilize insulin. The complexity of causes conspiring to diminish the bodys production or response to insulin, leading to high blood glucose and eventual development of diabetes, makes finding a single cure particularly difficult. While a cure has been elusive, critical research efforts in recent decades have led to significantly improved patient care, resulting in fewer complications and better health outcomes for individuals with diabetes. |
| Form 990, Part III, Line 4 | As a leader in diabetes research, and the only organization dedicated specifically to the research, education and advocacy required to improve the lives of all people with diabetes, the American Diabetes Association funds critical, innovative diabetes research and invests in promising scientists early in their careers. Our direct involvement in diabetes research extends back to the 1940s when Dr. Charles H. Best, one of four scientists credited with discovering insulin, provided the ADA with the framework and early leadership for a formalized diabetes research program. |
| Form 990, Part III, Line 4 | Since our Research Programs inception in 1952, we have been the leader in funding cutting-edge diabetes research, supporting nearly 4,800 research projects and investing more than 834.4 million in diabetes research. In 2018, the ADA supported 318 new and continuing research projects at 104 leading research institutions across the United States. The projects cover the broad spectrum of research approaches, including basic, clinical and translational science and address all types of diabetes, diabetes-related disease states and complications. |
| Form 990, Part III, Line 4 | The primary goals of the ADAs Research Program are to Support the highest quality science across the broad spectrum of diabetes research. Support investigators early in their careers to encourage them to dedicate their efforts to diabetes research. Support innovative research with a high potential to have a significant impact for patients with diabetes. |
| Form 990, Part III, Line 4 | Peer Review ProcessOne of the factors that sets American Diabetes Association-funded research apart and ensures that we are supporting the very best science is peer review. Peer review is a process whereby grant applications are reviewed and evaluated by individuals who are experts in the field or peers of the individual submitting the grant. ADA grant applications all undergo peer review by three or more volunteer experts who are themselves diabetes researchers. Reviewers provide both a score and detailed comments regarding the strengths and weaknesses of each grant they review. Scores from all reviewers for each grant are averaged to arrive at a composite merit score that is then used to determine which grants to support. |
| Form 990, Part III, Line 4 | Types of Research AwardsResearch awards are divided into four major categories that reflect our research goals and priorities, provide extraordinary opportunities for researchers from diverse backgrounds, and foster the professional development of young scientists interested in diabetes research. The categories are Investigator-Initiated Awards Core Program Pathway to Stop Diabetes Collaborative Targeted Research and Research Co-Support. Approximately 80 percent of American Diabetes Association-funded research falls under the Core Research Awards. The ADA uses a single annual grant application cycle for its Core Research Program, featuring a streamlined grant portfolio. In 2018, a total of 884 research grant applications were submitted. |
| Form 990, Part III, Line 4 | With donor-directed funding, the ADA supported a targeted initiative in 2018 to fund three postdoctoral fellows with clinical or translational research projects focused on understanding the cardiovascular complications of type 1 diabetes. The ADA hosted a research symposium on the Use of Real-World Data to Improve the Prevention and Care of Diabetes-Related Outcomes in Washington D.C. in November of 2018. The symposium offered presentations and discussion with the goal of driving consensus to accelerate guidance on the design and use of real-world data to improve the prevention and care of diabetes-related outcomes. ADA-supported researchers made significant progress in understanding how diabetes develops and progresses, and in identifying new ways to combat the disease. Notable advances include assessing the potential of community programs to combat health disparities in type 2 diabetes a novel therapy to prevent type 1 diabetes leading to a better understanding of why the immune system attacks insulin-producing beta-cells in type 1 diabetes and preserving eyesight in people with diabetes by studying a unique molecule that seems to play an important role in the development of diabetic retinopathy, a progressive complication of diabetes that affects nearly 100 million people worldwide and leads to blindness. |
| Form 990, Part III, Line 4 | Research Program OutcomesThe American Diabetes Association-funded researchers show an exemplary commitment to advancing their careers within the field of diabetes research. Within five years of their award 99 percent of the researchers we fund remain committed to diabetes research for at least five years 9 out of 10 researchers secure new funding within five years to expand their work, leveraging 7.36 for every 1 invested by the American Diabetes Association. |
| Form 990, Part III, Line 4 | Pathway to Stop DiabetesLaunched in 2013, the American Diabetes Association Pathway to Stop Diabetes initiative aims to inspire a new generation of diabetes researchers who are early in their career or are established but would like to expand their focus on diabetes research. Through awards of 1.625 million over the course of five to seven years, the program allows researchers to have the time and focus needed to explore new ideas. With a goal of funding 100 new diabetes researchers over the next decade, Pathway provides crucial support to individuals focusing on innovative ideas and transformational approaches that will lead to new discoveries in diabetes prevention and treatment. Importantly, Pathway is in addition to ongoing ADA research activities and is significantly expanding our research efforts. |
| Form 990, Part III, Line 4 | Six new Pathway awardees began their research projects in January 2018. During the 2018 calendar year these new awardees, along with the 23 Pathway scientists who were continuing in their terms of Pathway funding, collectively published 30 high-impact original research manuscripts and seven reviews. They delivered 151 presentations at scientific meetings. Through 2018, eight Pathway Initiator award recipients of nine funded to date have secured their first independent faculty positions. Ten patent applications have been filed by Pathway awardees to date. These outcomes demonstrate that the Pathway initiative continues to exceed its objectives and progress toward our vision of bringing 100 brilliant scientists to diabetes research. The Pathway scientists came together at the fourth annual Pathway to Stop Diabetes Symposium, held at the 78th Scientific Sessions in Orlando, Florida, where the newest cohort of Pathway awardees presented their project plans and progress to date. This exclusive symposium brought the awardees together with the Mentor Advisory Group, program sponsors, philanthropic supporters, and ADA leadership. The sixth annual Pathway to Stop Diabetes grant competition was held in 2018. The Mentor Advisory Group reviewed 89 outstanding nominations and selected three new Pathway awardees who began their grants in January 2018. With selection of these new awardees, the Pathway program has supported 32 outstanding investigators in total. 2018, the first group of scientists completed their terms of Pathway funding, which had started in 2014. These scientists, Kathleen Page, MD, of the University of Southern California Wolfgang Peti, PhD, of the University of Arizona and Joshua P. Thaler, MD, PhD, of the University of Washington, all completed their fifth and final year of their awards. Each of them has already added substantially to our understanding of diabetes and diabetes risk, and their contributions will continue throughout their careers in diabetes science, because they are now set up for success in conducting the kind of innovative, transformative research that holds promise to ultimately stop the health crisis that is diabetes. |
| Form 990, Part III, Line 4 | Scientific SessionsHeld annually, Scientific Sessions exemplifies the American Diabetes Associations leadership role in the global diabetes community, while providing a critical platform for driving diabetes awareness. Scientific Sessions is the worlds largest scientific and medical meeting focused on the latest basic and clinical science research related to diabetes and its complications. The 78th Scientific Sessions, held June 22 to 26, 2018 in Orlando, Florida, brought together more than 14,000 physicians, scientists, researchers, and health care providers. Over the course of five days, participants received exclusive access to more than 3,000 original research presentations, increasing their knowledge on the latest advances in diabetes research, care, and education. More than 3,000 abstracts were received. Of those received, 2,491 were presented as either Oral or Poster presentations. The remaining abstracts were either printed in the Journal Diabetes as Published Only or not accepted for presentation by the Scientific Sessions Meeting Planning Committee. |
| Form 990, Part III, Line 4 | 5th ANNUAL FOCUS ON FELLOWSThe 5th Annual Focus on Fellows program was held in conjunction with the 78th Scientific Sessions. This meeting is dedicated to fostering growth/development of future diabetes clinicians, researchers and leaders. The 131 attendees participated in a program that covered clinical, research and career development topics |
| Form 990, Part III, Line 4 | DIABETES IS PRIMARYDiabetes Is Primary, an education program for primary care providers, was piloted in several markets in 2018. More than 600 primary care providers participated in these five pilots. Diabetes Is Primary was also held as a Scientific Sessions preconference. During 2018, more than 10,000 CE certificates were provided to individuals who participated in the programs webcasts. |
| Form 990, Part III, Line 4 | WIN ADAThe Womens Interprofessional Network of the American Diabetes Association WIN ADA, ADAs membership group for female clinicians, scientists, and educators in diabetes, grew significantly in 2018 from 400 to 2,000 members. This group held its first mini symposium titled Overcoming Gender Gaps in Science, as well as an evening networking reception at the 78th Scientific Sessions, which approximately 300 professionals attended. |
| Form 990, Part III, Line 4 | We are Connected for Life. Just Imagine.The American Diabetes Association is a lot of things to a lot of different people. But the one thing we are to everyone is a connection point in the fight to cure diabetes to help people live a better life. Just imagine. Imagine the day when diabetes will no longer devastate our families and communities, our neighbors near and far. When a parent doesnt have to hear that their child has an incurable disease that brings with it not only sleepless nights, but constant fears about possible complications and diabetes related discrimination. When nobody has to worry anymore about blood glucose highs and lows and whether that blurred vision is the beginning of a life without sight. When a family can gather at a family reunion and create happy memories instead of having to gather at a graveside to say goodbye to a loved one who has lost their battle against diabetes. We know that, together, we can stop this dreadful disease and realize our vision life free of diabetes and all its burdens. |
| Form 990, Part VI, Section A, Line 4 | The bylaws of the American Diabetes Association Research Foundation were revised in 2018 to change the composition of the Board of Directors. |
| Software ID: | 18007340 |
| Software Version: | 19.1.1.0 |